Long-Term Follow-Up of AvenCell Sponsored CAR-T Cell Clinical Trials

Enrolling by invitation

Conditions studied: B-cell Lymphoma, Chronic Lymphocytic Leukemia, Hematologic Malignancy, AML (Acute Myelogenous Leukemia), Prostate Cancer

In brief

The goal of this clinical study is to learn more about the long-term safety, effectiveness and prolonged action of patients who participated in an AvenCell-sponsored clinical trial and received treatment with AvenCell's UniCAR or RevCAR platforms.

Key facts

Study ID

NCT07474051

Run by

AvenCell Therapeutics, Inc.

People needed

178

Starts

2026-01-29

Expected to finish

2041-01-30

Last updated by the study team

2026-03-16

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participant who received an AVC-CAR-T cell therapy within an AVC-sponsored clinical trial.
• Participant signed written informed consent for the AVC-PERSIST study.

You may not qualify if…

• Participant is unable to provide written informed consent.
• Participant is unable to comply with study requirements in the eyes of the Investigator.

Where it is running

• Charité Universitätsmedizin Berlin — Berlin, Germany
• Technische Universitaet Dresden - Universitaetsklinikum Carl Gustav Carus — Dresden, Germany
• Universitätsklinikum Marburg — Marburg, Germany
• Klinikum der Universität (LMU) Muenchen — Munich, Germany
• Universitatsklinikum Ulm — Ulm, Germany

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.